ARHGEF16 Knockout HT29 Polyclonal Cells are a heterogenous population of HT29 cells engineered by CRISPR/Cas9-mediated gene disruption at the ARHGEF16 locus, yielding a polyclonal knockout cell model for functional studies of this Rho guanine nucleotide exchange factor. This product provides a loss-of-function system in a human colorectal adenocarcinoma background without clonal selection, enabling researchers to examine gene function in a context that preserves natural population variability.
The host cell line HT29 is a well-established human colon adenocarcinoma cell line with epithelial morphology, widely used for investigating colorectal cancer biology, intestinal epithelial differentiation, and barrier function. These cells form polarized monolayers and express junctional proteins, making them a relevant model for studying the intestinal epithelium in both homeostasis and disease states such as inflammatory bowel disease and colorectal tumor progression.
ARHGEF16 encodes a guanine nucleotide exchange factor that specifically activates the small GTPase RhoA by catalyzing the exchange of GDP for GTP. RhoA activation stimulates downstream kinases including ROCK1, which phosphorylates MYPT1 and myosin light chain (MLC) to promote actin stress fiber formation and focal adhesion assembly. ARHGEF16 signaling is initiated by upstream inputs such as integrin engagement, epidermal growth factor receptor (EGFR) activation, transforming growth factor-beta receptor (TGF??R) stimulation, and mechanical stress. This cascade is further modulated by GTPase-activating proteins (GAPs) and interacting partners such as Rac1, Cdc42, PAK1, DLC1, and ??-catenin. In HT29 cells, ARHGEF16-mediated RhoA activation drives cytoskeletal reorganization, cell migration, and adhesion dynamics.
Disruption of ARHGEF16 in HT29 cells is predicted to attenuate RhoA-ROCK signaling, impairing actin stress fiber formation, cell motility, and epithelial barrier integrity. This knockout model holds particular significance for colorectal cancer research, where aberrant Rho GTPase activity promotes tumor invasion and metastasis. By enabling the study of reduced ARHGEF16 function, these polyclonal cells facilitate dissection of the molecular links between integrin-mediated adhesion, cytoskeletal remodeling, and the maintenance of tight junctions, providing insights into mechanisms of cancer cell dissemination and intestinal barrier dysfunction.
This polyclonal knockout cell product is suited for a broad range of functional assays, including wound healing and Transwell migration assays to evaluate cell motility, RhoA activation G-LISA to quantify GTP-bound RhoA, immunofluorescence imaging of actin stress fibers and focal adhesion markers, and transepithelial electrical resistance (TEER) measurements for barrier integrity. Additional applications encompass Western blotting for ARHGEF16 and phospho-MLC levels, RT-qPCR profiling of downstream target genes, and co-immunoprecipitation analysis of RhoA interactions. The ARHGEF16 Knockout HT29 Polyclonal Cells are a valuable tool for drug target validation studies focusing on Rho-ROCK pathway inhibitors. For technical support or guidance on assay adaptation, please contact Ascent Research.
